Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Head and Neck Cancer

  Free Subscription


8 Anticancer Res
2 BMC Cancer
1 Clin Nucl Med
1 Gastrointest Endosc
1 Head Neck
3 Oral Oncol
1 PLoS One
1 Radiother Oncol
6 Thyroid

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Anticancer Res

  1. KING K, Rauch R, Roy S, Menyok O, et al
    Impact of Routine Surveillance Imaging on Recurrence in Sinonasal Malignancies.
    Anticancer Res. 2022;42:5449-5455.
    PubMed         Abstract available

  2. AOYAMA T, Maezawa Y, Hara K, Ju M, et al
    The Clinical Impact of Other Primary Cancer in Patients Who Received Curative Treatment for Esophageal Cancer.
    Anticancer Res. 2022;42:5635-5641.
    PubMed         Abstract available

  3. SATO H, Nishikawa K, Hamakawa T, Kusunoki C, et al
    Evaluating Neoadjuvant Chemotherapy for Lower Esophageal Squamous Cell Carcinoma by Measuring Esophageal Wall Thickness.
    Anticancer Res. 2022;42:5655-5662.
    PubMed         Abstract available

  4. CHO JS, Kim HK
    Thyroglobulin Levels as a Predictor of Papillary Cancer Recurrence After Thyroid Lobectomy.
    Anticancer Res. 2022;42:5619-5627.
    PubMed         Abstract available

  5. REUTER I, Muller HH, Wiegand S
    Prognostic Significance of the Nodal Ratio and Number of Positive Nodes in Patients With Squamous Cell Carcinomas of the Head and Neck.
    Anticancer Res. 2022;42:5567-5570.
    PubMed         Abstract available

  6. KYLMA AK, Sorsa T, Jouhi L, Mustonen HK, et al
    Prognostic Role of Porphyromonas gingivalis Gingipain Rgp and Matrix Metalloproteinase 9 in Oropharyngeal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:5415-5430.
    PubMed         Abstract available

  7. SU PH, Hsu CC, Hsueh SW, Hung CY, et al
    Potential Utility of the Mallampati Score for Prediction of Treatment Compliance and Safety Profiles of Patients With Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
    Anticancer Res. 2022;42:5609-5618.
    PubMed         Abstract available

  8. LANDSTROM F, Reizenstein J, Kristiansson S
    Detection of Recurrence After Primary Treatment for Oropharyngeal Carcinoma.
    Anticancer Res. 2022;42:5597-5600.
    PubMed         Abstract available

    BMC Cancer

  9. NISHIMURA A, Yokota T, Hamauchi S, Onozawa Y, et al
    Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer.
    BMC Cancer. 2022;22:1101.
    PubMed         Abstract available

  10. SHEN Y, Huang Q, Ji M, Hsueh CY, et al
    Smoking-mediated nicotinic acetylcholine receptors (nAChRs) for predicting outcomes for head and neck squamous cell carcinomas.
    BMC Cancer. 2022;22:1093.
    PubMed         Abstract available

    Clin Nucl Med

  11. OPALINSKI L, Schmitz S, Van Eeckhout P, d'Abadie P, et al
    Hyoepiglottic Rheumatoid Nodule Mimicking Head and Neck Malignancy on 18F-FDG PET/CT.
    Clin Nucl Med. 2022 Oct 27. pii: 00003072-990000000-00334.
    PubMed         Abstract available

    Gastrointest Endosc

  12. FREDERIKS CN, Overwater A, Alvarez Herrero L, Alkhalaf A, et al
    Comparison of focal cryoballoon ablation with 10- and 8-second doses for treatment of Barrett's esophagus-related neoplasia: results from a prospective European multicenter study (with video).
    Gastrointest Endosc. 2022;96:743-751.
    PubMed         Abstract available

    Head Neck

  13. KIM DH, Kim SW, Hwang SH
    Efficacy of optical coherence tomography in the diagnosing of oral cancerous lesion: systematic review and meta-analysis.
    Head Neck. 2022 Oct 28. doi: 10.1002/hed.27232.
    PubMed         Abstract available

    Oral Oncol

  14. CHABRILLAC E, Lebars S, Breuskin I, Thariat J, et al
    Pregnancy-associated head and neck cancer:a partnership between theCORASSO patient association and theREFCOR physician networkto study a pathology of extremely rare occurrence.
    Oral Oncol. 2022;135:106223.

  15. GOVINDARASU M, Prathap L, Govindasamy R
    Histone deacetylase inhibitors regulate the oral cancer via PI3K/AKT signaling pathway.
    Oral Oncol. 2022;135:106221.

  16. DENNIS MJ, Sacco AG, Qi Y, Bykowski J, et al
    A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2022;135:106219.
    PubMed         Abstract available

    PLoS One

  17. ZHU Z, Yu S, Niu K, Wang P, et al
    LGR5 promotes invasion and migration by regulating YAP activity in hypopharyngeal squamous cell carcinoma cells under inflammatory condition.
    PLoS One. 2022;17:e0275679.
    PubMed         Abstract available

    Radiother Oncol

  18. ROESCH J, Oertel M, Wegen S, Trommer M, et al
    Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis.
    Radiother Oncol. 2022 Oct 20. pii: S0167-8140(22)04502.
    PubMed         Abstract available


  19. DIGENNARO C, Vahdat V, Jalali M, Toumi A, et al
    Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis.
    Thyroid. 2022 Aug 23. doi: 10.1089/thy.2022.0269.
    PubMed         Abstract available

  20. BAL C, Satapathy S, Tupalli A, Ballal S, et al
    Propensity Score Matched Outcome Analysis of Lobar Ablation versus Completion Thyroidectomy in Low-risk Differentiated Thyroid Cancer Patients: Median Follow-up of 11 Years.
    Thyroid. 2022 Aug 18. doi: 10.1089/thy.2022.0234.
    PubMed         Abstract available

  21. LI C, Gao Y, Zhou P, Yue T, et al
    Comparison of the robotic bilateral axillo-breast approach and conventional open thyroidectomy in pediatric patients: a retrospective cohort study.
    Thyroid. 2022 Aug 9. doi: 10.1089/thy.2022.0242.
    PubMed         Abstract available

  22. JERKOVICH F, Abelleira E, Bueno F, Guerrero L, et al
    Active surveillance of small metastatic lymph nodes as an alternative to surgery in selected patients with low risk papillary thyroid cancer: A retrospective cohort study.
    Thyroid. 2022 Jul 25. doi: 10.1089/thy.2022.0302.
    PubMed         Abstract available

  23. BUSAIDY N, Konda B, Wei L, Wirth LJ, et al
    Dabrafenib vs dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer - results of a randomized, phase 2, open-label, multicenter trial.
    Thyroid. 2022 Jun 4. doi: 10.1089/thy.2022.0115.
    PubMed         Abstract available

  24. WIJEWARDENE A, Gill AJ, Gild M, Learoyd DL, et al
    A retrospective cohort study with prospective validation of predictors of differentiated thyroid cancer outcomes.
    Thyroid. 2022 May 27. doi: 10.1089/thy.2021.0563.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.